ArticleESMO real world data and digital oncology2026
Treatment and survival of
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Human epidermal growth factor receptor 2 (HER2)-targeted therapy has improved survival in HER2-positive metastatic breast cancer (MBC). Real-world practice may differ across oncologic networks, even within countries with uniform treatment guidelines. We assessed regional variation in first-line treatment and overall survival (OS) among patients with Patients and methods: Data from the Netherlands Cancer Registry were analysed. The registry includes seven regions, anonymised as A-G. Crude regional proportions of first-line HER2-targeted therapy were described. Inverse probability of treatment weighting (IPTW) was applied, with region as the exposure. Risk ratios for receiving HER2-targeted therapy were estimated using IPTW-adjusted Poisson regression. OS was analysed using the Kaplan-Meier method and IPTW-adjusted Cox regression, additionally adjusting for baseline covariates and first-line treatment. Results: Among 2158 patients, use of first-line HER2-targeted therapy ranged from 70% (region F) to 88% (region C). After adjustment, no regional differences were observed ( Conclusions: No large regional differences in first-line HER2-targeted therapy were observed among
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.